ConductScience.org, home

Paper42935367PubMed

An Australian Narrative Review of Adoptive Cellular Therapies in Malignancy: Expanding Indications, Referral Pathways and Safety Beyond Specialist Centres.

Childs S and 15 others. Med J Aust, 2026.

Cite this record

ConductScience Library. An Australian Narrative Review of Adoptive Cellular Therapies in Malignancy: Expanding Indications, Referral Pathways and Safety Beyond Specialist Centres. Papers, record 42935367. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42935367

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
An Australian Narrative Review of Adoptive Cellular Therapies in Malignancy: Expanding Indications, Referral Pathways and Safety Beyond Specialist Centres.
Journal
Med J Aust
Year
2026
Publication types
Journal Article, Review
Revised in PubMed
2026-10-29

Source PubMed

Authors16

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Childs SSarah
2Ma DDavid
3Rodrigues AAnthony
4Massey JJennifer
5Cosman RRasha
6Chin VVenessa
7Girgis LLaila
8Lynam JJames
9Lau PPeterhttps://orcid.org/0000-0003-1071-7956
10Withers BBarbara
11Joshua AMAnthony M
12Tran BBen
13Desai JJayesh
14Harrison SJSimon J
15Moore JJohn
16Liu JJia

Source PubMed

Download CSV of authors

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
NeoplasmsMajor topic
Immunotherapy, AdoptiveMajor topic
Humans
Australia
Referral and Consultation

References55

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133979178Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.J Clin Oncol2021https://conductscience.org/library/papers/33979178PubMed
240378343Inequalities in CAR T-cell therapy access for US patients with relapsed/refractory DLBCL: a SEER-Medicare data analysis.Blood Adv2025https://conductscience.org/library/papers/40378343PubMed
336717905CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances.Mol Cancer2023https://conductscience.org/library/papers/36717905PubMed
437420216Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments.J Transl Med2023https://conductscience.org/library/papers/37420216PubMed
530518633A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers.Clin Cancer Res2019https://conductscience.org/library/papers/30518633PubMed
638683966HA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation.Blood2024https://conductscience.org/library/papers/38683966PubMed
740089329Tumor-Infiltrating Lymphocyte Therapy: A New Frontier.Transplant Cell Ther2025https://conductscience.org/library/papers/40089329PubMed
837872225CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial.Nat Med2023https://conductscience.org/library/papers/37872225PubMed
934175021
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Lancet2021https://conductscience.org/library/papers/34175021PubMed
1034279805Travel-Related Economic Burden of Chimeric Antigen Receptor T Cell Therapy Administration by Site of Care.Adv Ther2021https://conductscience.org/library/papers/34279805PubMed
1139603960Advances in cell therapy: progress and challenges in hematological and solid tumors.Trends Pharmacol Sci2024https://conductscience.org/library/papers/39603960PubMed
1241543441Global access to commercial CAR T-cell therapies: a cross-sectional study of health technology assessment across the G20 countries.Blood2026https://conductscience.org/library/papers/41543441PubMed
1339697210The current socioeconomic and regulatory landscape of immune effector cell therapies.Front Med (Lausanne)2024https://conductscience.org/library/papers/39697210PubMed
1441530803The safety and efficacy of GD2-targeted CAR-T cells in patients with neuroblastoma: a systematic review and meta-analysis.Eur J Med Res2026https://conductscience.org/library/papers/41530803PubMed
1539837618Art of TIL immunotherapy: SITC's perspective on demystifying a complex treatment.J Immunother Cancer2025https://conductscience.org/library/papers/39837618PubMed
163264384Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.N Engl J Med1988https://conductscience.org/library/papers/3264384PubMed
1731921205The Intriguing History of Cancer Immunotherapy.Front Immunol2019https://conductscience.org/library/papers/31921205PubMed
1821282551Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.J Clin Oncol2011https://conductscience.org/library/papers/21282551PubMed
1936604431Neoantigens: promising targets for cancer therapy.Signal Transduct Target Ther2023https://conductscience.org/library/papers/36604431PubMed
2036906275Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome.Transplant Cell Ther2023https://conductscience.org/library/papers/36906275PubMed

See all 55 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42935367

GET https://conductscience.org/api/papers/v1/42935367/references?page=2